Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[
2-[(211)At]astato-α-methyl-L-phenylalanine (2-[(211)At]AAMP)
L-type amino acids transporter 1 (LAT1)
Targeted radionuclide therapy
α-Emitter
Journal
Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420
Informations de publication
Date de publication:
Historique:
received:
29
05
2020
revised:
24
08
2020
accepted:
25
08
2020
pubmed:
12
9
2020
medline:
28
9
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Targeted α-radionuclide therapy has attracted attention as a promising therapy for refractory cancers. However, the application is limited to certain types of cancer. Since L-type amino acid transporter 1 (LAT1) is highly expressed in various human cancers, we prepared an LAT1-selective α-radionuclide-labeled amino acid analog, 2-[ 2-[ 2-[ 2-[ This is the first report of an LAT1-targeting radiopharmaceutical for α-radionuclide therapy; this agent would be applicable for the treatment of various types of cancer.
Identifiants
pubmed: 32916470
pii: S0969-8051(20)30160-8
doi: 10.1016/j.nucmedbio.2020.08.003
pii:
doi:
Substances chimiques
Astatine-211
0
Large Neutral Amino Acid-Transporter 1
0
Phenylalanine
47E5O17Y3R
Astatine
XI595HAL7H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-22Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no conflict of interest.